2026 NPPES data Hematology & Oncology Physician NPI 1497921829 M.D.
Verify on CMS →

REVATHI ANGITAPALLI, M.D.

Hematology & Oncology Physician in ARLINGTON, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
840
Medicare Part D claims · 229 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
79%
generic claims · 21% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
75/100
▼ 8 pts below national avg 83.1 · [object Object]
Industry payments
$3.8K
134 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: REVATHI ANGITAPALLI, M.D. is a Hematology & Oncology Physician ([object Object]) practicing in ARLINGTON, Texas with a Medicare Part D prescribing footprint of 840 claims across 229 beneficiaries — 21% brand-name prescribing . Their CMS MIPS Final Score of 75/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities . Industry payments of $3.8K across 134 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: REVATHI ANGITAPALLI, M.D. reported a CMS MIPS final score of 75 out of 100, below the 83.1 national average, and filed 840 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

REVATHI ANGITAPALLI, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

REVATHI ANGITAPALLI, M.D. at a glance

Below national average

NPI registry status

Active

Issued 05/06/2008

NPI 1497921829

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

840 1% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

75/100 8.099999999999994% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Texas

How Hematology & Oncology Physician compares to other specialties among Texas providers

Texas providers

Hematology & Oncology Physician share within Texas

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Texas

Medicare quality performance — MIPS

REVATHI ANGITAPALLI, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

Below national average
MIPS Final Score
75/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 75/100 vs national avg 83.1

0%100%National avg83%75%
MIPS final score (Hematology & Oncology Physician) — 75/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

REVATHI ANGITAPALLI, M.D. is a Hematology & Oncology Physician provider practicing in ARLINGTON, Texas, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1497921829. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

REVATHI ANGITAPALLI, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 515 W MAYFIELD RD STE 102, ARLINGTON, TX, 76014, with a listed phone of (817) 759-7000. NPI 1497921829 was issued on 05/06/2008. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ANGITAPALLI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 840 prescription claims written by this provider, covering 229 Medicare beneficiaries and totaling roughly $1.9 million in drug spend, split 21% brand-name and 79% generic by claim count, with an opioid prescribing rate of 4.3%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

515 W MAYFIELD RD STE 102
ARLINGTON, TX 76014

Provider Details

NPI 1497921829
Specialty Hematology & Oncology Physician
Credentials M.D.
Gender Female
NPI Issued 05/06/2008

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

75
Final Score
Avg: 83.1

Reporting: Group practice

Hospital and facility affiliations

Facilities where REVATHI ANGITAPALLI, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

ONCOLOGY HEMATOLOGY CONSULTANTS, PA
WEATHERFORD, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for REVATHI ANGITAPALLI, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$3.8K

Largest payer

Novartis Pharmaceuticals Corporation

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to REVATHI ANGITAPALLI, M.D.. To verify REVATHI ANGITAPALLI, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

REVATHI ANGITAPALLI, M.D. — brand share 21.0%
Specialty average (est.)

21% brand-name claims vs 79% generic, on 840 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

840
Total Claims
$1.9M
Total Drug Cost
229
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,412
Total Day Supply
40,503
Brand vs Generic
21% brand / 79% generic
Brand Drug Cost
$1.8M
Generic Drug Cost
$110K
Opioid Claims
36 (4.3% rate)
Antibiotic Claims
14

Patient Demographics

Average Patient Age
73.3 years
Avg HCC Risk Score
1.80
Gender Split
84% female / 16% male
Age Distribution
<65: 13, 65-74: 120, 75-84: 81, 85+: 15

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Anastrozole
254
Tamoxifen Citrate
64
Abiraterone Acetate
57
Letrozole
44
Eliquis
Apixaban
43
Alendronate Sodium
34
Revlimid
Lenalidomide
25
Verzenio
Abemaciclib
25
Exemestane
22
Hydroxyurea
22

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How REVATHI ANGITAPALLI, M.D. fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

REVATHI ANGITAPALLI, M.D.'s 840 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as ANGITAPALLI.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is REVATHI ANGITAPALLI, M.D.'s specialty?
REVATHI ANGITAPALLI, M.D. specializes in Hematology & Oncology Physician and practices in ARLINGTON, Texas. Credentials: M.D..
How much does REVATHI ANGITAPALLI, M.D. prescribe under Medicare Part D?
In 2023, REVATHI ANGITAPALLI, M.D. wrote 840 Medicare Part D claims totaling $1.9M in drug costs for 229 beneficiaries.
What is REVATHI ANGITAPALLI, M.D.'s Medicare quality score?
REVATHI ANGITAPALLI, M.D. has a CMS MIPS Final Score of 75/100. The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is REVATHI ANGITAPALLI, M.D. located?
REVATHI ANGITAPALLI, M.D. is located at 515 W MAYFIELD RD STE 102, ARLINGTON, TX, 76014. Phone: (817) 759-7000.
What is REVATHI ANGITAPALLI, M.D.'s NPI number?
REVATHI ANGITAPALLI, M.D.'s National Provider Identifier (NPI) is 1497921829, issued on 05/06/2008.
Does REVATHI ANGITAPALLI, M.D. prescribe more brand-name or generic drugs?
REVATHI ANGITAPALLI, M.D.'s prescribing is 21% brand-name and 79% generic drugs by claim count, with $1.8M in brand drug costs.
Does REVATHI ANGITAPALLI, M.D. prescribe opioids?
Yes, REVATHI ANGITAPALLI, M.D. had 36 opioid claims in 2023 with an opioid prescribing rate of 4.3%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does REVATHI ANGITAPALLI, M.D. prescribe most often?
Based on 2023 Medicare Part D data, REVATHI ANGITAPALLI, M.D.'s most frequently prescribed drugs include Anastrozole, Tamoxifen Citrate, Abiraterone Acetate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does REVATHI ANGITAPALLI, M.D. accept Medicare?
REVATHI ANGITAPALLI, M.D. appears in CMS Medicare data with 840 Part D claims and 229 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify REVATHI ANGITAPALLI, M.D.'s credentials?
REVATHI ANGITAPALLI, M.D.'s NPI is 1497921829 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology